Pexelizumab Biosimilar – Anti-C5 mAb – Research Grade from ProteoGenix; catalogue PX-TA1059; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Introduction to Pexelizumab Biosimilar – A Promising Anti-C5 mAb for Therapeutic Targeting Pexelizumab Biosimilar, also known as anti-C5 mAb, is a promising therapeutic antibody that targets the complement protein C5. This biosimilar is a research grade monoclonal antibody (mAb) that has shown great potential in treating diseases related to complement dysregulation. In this article, we will explore the structure, activity, and potential applications of Pexelizumab Biosimilar.
Pexelizumab Biosimilar is a fully humanized monoclonal antibody that is designed to mimic the structure and function of the natural antibody against C5. It is composed of two identical heavy chains and two identical light chains, held together by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain one constant domain (CL) and one variable domain (VL).
The variable domains of Pexelizumab Biosimilar are responsible for binding to the complement protein C5. They contain antigen-binding sites that specifically recognize and bind to a specific region on C5, thus inhibiting its activity. The constant domains, on the other hand, are responsible for mediating effector functions such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.
Pexelizumab Biosimilar works by inhibiting the activity of the complement protein C5. The complement system is an important part of the immune system that helps in the recognition and elimination of foreign invaders. However, dysregulation of the complement system has been linked to various diseases, including autoimmune disorders, inflammatory diseases, and organ transplant rejection.
C5 is a key component of the complement system and plays a crucial role in the formation of the membrane attack complex (MAC), which causes cell lysis. Pexelizumab Biosimilar binds to C5 and prevents its cleavage into C5a and C5b, thereby inhibiting the formation of MAC and reducing inflammation and tissue damage.
Pexelizumab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of diseases related to complement dysregulation. One of the potential applications of this biosimilar is in the treatment of autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis. By inhibiting C5, Pexelizumab Biosimilar can reduce inflammation and tissue damage associated with these diseases.
Another potential application of Pexelizumab Biosimilar is in the prevention of organ transplant rejection. The complement system plays a major role in the rejection of transplanted organs, and by targeting C5, Pexelizumab Biosimilar can potentially improve the success rates of organ transplantation.
In addition, Pexelizumab Biosimilar has also shown promising results in the treatment of inflammatory diseases such as atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. By inhibiting C5, this biosimilar can reduce the risk of organ damage and improve the overall quality of life for patients.
Pexelizumab Biosimilar, also known as anti-C5 mAb, is a promising therapeutic antibody that targets the complement protein C5. It is a fully humanized monoclonal antibody with a specific structure that allows it to bind to C5 and inhibit its activity. This biosimilar has shown great potential in treating diseases related to complement dysregulation, including autoimmune disorders, organ transplant rejection, and inflammatory diseases. With further research and development, Pexelizumab Biosimilar has the potential to become a valuable treatment option for patients in need.
ProteoGenix catalogue number PX-TA1059. For research use only.
Target: Pexelizumab Biosimilar – Anti-C5 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Pexelizumab Biosimilar – Anti-C5 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
